Nextcure Stock Today
| NXTC Stock | USD 13.10 0.14 1.06% |
PerformanceFair
| Odds Of DistressHigh
|
NextCure is trading at 13.10 as of the 17th of February 2026, a 1.06 percent decrease since the beginning of the trading day. The stock's open price was 13.24. NextCure has more than 68 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of November 2025 and ending today, the 17th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of May 2019 | Category Healthcare | Classification Health Care |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. The company has 3.51 M outstanding shares of which 47.51 K shares are now shorted by private and institutional investors with about 1.46 trading days to cover. More on NextCure
Moving against NextCure Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NextCure Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, NextCure can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on NextCure's use of financial leverage and reveals what portion of NextCure's asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NextCure (NXTC) is traded on NASDAQ Exchange in USA and employs 43 people. NextCure is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.92 M. NextCure conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.51 M outstanding shares of which 47.51 K shares are now shorted by private and institutional investors with about 1.46 trading days to cover.
NextCure currently holds about 185.49 M in cash with (40.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68.
Check NextCure Probability Of Bankruptcy
Ownership AllocationThe market capitalization of NextCure is $45.92 Million. Over half of NextCure's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check NextCure Ownership Details
NextCure Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sio Capital Management, Llc | 2025-03-31 | 130 K | |
| Adar1 Capital Management Llc | 2025-03-31 | 120 K | |
| Armistice Capital, Llc | 2025-03-31 | 104 K | |
| Citadel Advisors Llc | 2025-03-31 | 90.6 K | |
| Barclays Plc | 2025-03-31 | 67.5 K | |
| State Street Corp | 2025-03-31 | 65.4 K | |
| Northern Trust Corp | 2025-03-31 | 47.5 K | |
| Ieq Capital, Llc | 2025-03-31 | 37.3 K | |
| Schonfeld Strategic Advisors Llc | 2025-03-31 | 18.9 K | |
| Sofinnova Ventures | 2025-03-31 | 2.7 M | |
| Affinity Asset Advisors, Llc | 2025-03-31 | 2.3 M |
NextCure Historical Income Statement
NextCure Stock Against Markets
NextCure Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Steven CPA | Chief Officer | Profile | |
| Sebastien Maloveste | Senior Development | Profile | |
| Sourav Kundu | Senior Manufacturing | Profile | |
| Kevin Shaw | General Counsel | Profile | |
| Michael MSBA | CEO, CoFounder | Profile | |
| Lieping MD | CoFounder Board | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Will Biotechnology sector continue expanding? Could NextCure diversify its offerings? Factors like these will boost the valuation of NextCure. Anticipated expansion of NextCure directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NextCure data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between NextCure's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NextCure should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, NextCure's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.